NEW YORK, Sept. 27, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: EYEN) (“Eyenovia” or the “Company”), an ophthalmic technology company with two FDA-approved products and a late-stage asset in development for ...
Some results have been hidden because they may be inaccessible to you